Ipsen (FR:IPN) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ipsen’s drug Kayfanda® (odevixibat) has received EU approval to treat cholestatic pruritus in patients over six months old with Alagille Syndrome, a rare liver disease. The approval is based on Phase III trial results which demonstrated significant improvement in itch severity and sleep quality, with a safety profile similar to placebo. This marks a significant advancement in Ipsen’s portfolio for rare cholestatic liver diseases, also noted for their recent EU approval of Iqirvo® (elafibranor) for Primary Biliary Cholangitis.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.